Martin D. Madaus Buys 1,800 Shares of Repligen Corporation (NASDAQ:RGEN) Stock

Repligen Corporation (NASDAQ:RGEN) Director Martin D. Madaus purchased 1,800 shares of the company’s stock in a transaction dated Friday, August 8th. The shares were purchased at an average price of $112.13 per share, for a total transaction of $201,834.00. Following the completion of the purchase, the director owned 1,800 shares of the company’s stock, valued at approximately $201,834. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Repligen Stock Up 4.7%

RGEN stock opened at $127.15 on Thursday. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32. Repligen Corporation has a 12 month low of $102.96 and a 12 month high of $182.52. The firm has a market capitalization of $7.15 billion, a PE ratio of -508.58, a P/E/G ratio of 2.23 and a beta of 1.05. The company’s 50 day simple moving average is $122.58 and its 200-day simple moving average is $133.62.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%. The company had revenue of $182.37 million for the quarter, compared to analysts’ expectations of $174.62 million. During the same period in the previous year, the business posted $0.40 EPS. The business’s quarterly revenue was up 14.8% on a year-over-year basis. Equities analysts expect that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Raymond James Financial Inc. acquired a new position in shares of Repligen in the fourth quarter valued at approximately $52,492,000. Treasurer of the State of North Carolina grew its stake in Repligen by 0.7% in the 4th quarter. Treasurer of the State of North Carolina now owns 24,500 shares of the biotechnology company’s stock worth $3,527,000 after acquiring an additional 160 shares during the period. Sterling Capital Management LLC grew its stake in Repligen by 51.8% in the 4th quarter. Sterling Capital Management LLC now owns 2,982 shares of the biotechnology company’s stock worth $429,000 after acquiring an additional 1,017 shares during the period. Townsquare Capital LLC raised its holdings in Repligen by 6.4% in the 4th quarter. Townsquare Capital LLC now owns 15,004 shares of the biotechnology company’s stock valued at $2,160,000 after acquiring an additional 898 shares during the last quarter. Finally, Synovus Financial Corp purchased a new position in shares of Repligen during the 4th quarter worth $941,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have issued reports on RGEN shares. JPMorgan Chase & Co. dropped their target price on Repligen from $200.00 to $190.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 29th. Wolfe Research raised Repligen from a “peer perform” rating to an “outperform” rating and set a $160.00 price objective on the stock in a report on Tuesday, April 29th. Royal Bank Of Canada raised their target price on Repligen from $193.00 to $204.00 and gave the company an “outperform” rating in a report on Wednesday, July 30th. Stephens upgraded shares of Repligen to an “overweight” rating and set a $160.00 target price on the stock in a research report on Tuesday, July 22nd. Finally, Wall Street Zen downgraded shares of Repligen from a “buy” rating to a “hold” rating in a report on Sunday, June 29th. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $169.45.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.